AU2022269811A1 - Orexin receptor agonists and uses thereof - Google Patents

Orexin receptor agonists and uses thereof Download PDF

Info

Publication number
AU2022269811A1
AU2022269811A1 AU2022269811A AU2022269811A AU2022269811A1 AU 2022269811 A1 AU2022269811 A1 AU 2022269811A1 AU 2022269811 A AU2022269811 A AU 2022269811A AU 2022269811 A AU2022269811 A AU 2022269811A AU 2022269811 A1 AU2022269811 A1 AU 2022269811A1
Authority
AU
Australia
Prior art keywords
compound
alkyl
mmol
cycloalkyl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022269811A
Other languages
English (en)
Inventor
Claudia BEATO
Prafulkumar CHOVATIA
Davide MARINELLI
Gilles Ouvry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jazz Pharmaceuticals Ireland Ltd
Original Assignee
Jazz Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jazz Pharmaceuticals Ireland Ltd filed Critical Jazz Pharmaceuticals Ireland Ltd
Publication of AU2022269811A1 publication Critical patent/AU2022269811A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2022269811A 2021-05-03 2022-05-03 Orexin receptor agonists and uses thereof Pending AU2022269811A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163183321P 2021-05-03 2021-05-03
US63/183,321 2021-05-03
PCT/EP2022/061851 WO2022233872A1 (en) 2021-05-03 2022-05-03 Orexin receptor agonists and uses thereof

Publications (1)

Publication Number Publication Date
AU2022269811A1 true AU2022269811A1 (en) 2023-11-16

Family

ID=81940742

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022269811A Pending AU2022269811A1 (en) 2021-05-03 2022-05-03 Orexin receptor agonists and uses thereof

Country Status (12)

Country Link
US (1) US20240254143A1 (https=)
EP (1) EP4334323A1 (https=)
JP (1) JP2024516033A (https=)
KR (1) KR20240004802A (https=)
CN (1) CN117616030A (https=)
AU (1) AU2022269811A1 (https=)
BR (1) BR112023022050A2 (https=)
CA (1) CA3217403A1 (https=)
IL (1) IL308099A (https=)
MX (1) MX2023012971A (https=)
TW (1) TW202309051A (https=)
WO (1) WO2022233872A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI4065585T3 (fi) 2019-11-25 2025-09-26 Alkermes Inc Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
US12006330B2 (en) 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
WO2023081094A1 (en) * 2021-11-04 2023-05-11 University Of Washington Novel spirocyclic compounds as klhdc2 ligands
EP4658660A1 (en) 2023-01-31 2025-12-10 Jazz Pharmaceuticals Ireland Limited Macrocyclic orexin receptor agonists and uses thereof
CN116478076A (zh) * 2023-04-26 2023-07-25 南京优氟医药科技有限公司 一种(2s,4s)-1-叔丁氧羰基-2-(二氟甲基)-4-羟基吡咯烷的制备方法
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
TW202542165A (zh) 2023-12-19 2025-11-01 瑞士商愛杜西亞製藥有限公司 大環食慾素激動劑

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69318854T2 (de) * 1993-03-04 1998-10-08 Pfizer Spiroazacyclischderivate als substanz p antagonisten
DE69923744T2 (de) * 1998-10-23 2006-02-23 Pfizer Inc. 1,3,8-Triazaspiro[4,5] decanon Verbindungen als orl1-receptor Agonisten
WO2011076747A1 (en) * 2009-12-21 2011-06-30 Novartis Ag Diaza-spiro[5.5]undecanes as orexin receptor antagonists
US20120101110A1 (en) * 2010-10-26 2012-04-26 Sangamesh Badiger Diaza-spiro[5.5]undecanes
PL3411358T3 (pl) * 2016-02-04 2022-02-28 Takeda Pharmaceutical Company Limited Podstawiony związek piperydynowy i jego zastosowanie
JP7413261B2 (ja) * 2018-06-29 2024-01-15 武田薬品工業株式会社 複素環化合物およびその用途
US11098029B2 (en) * 2019-02-13 2021-08-24 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists

Also Published As

Publication number Publication date
MX2023012971A (es) 2024-01-16
JP2024516033A (ja) 2024-04-11
BR112023022050A2 (pt) 2023-12-26
US20240254143A1 (en) 2024-08-01
EP4334323A1 (en) 2024-03-13
CN117616030A (zh) 2024-02-27
KR20240004802A (ko) 2024-01-11
WO2022233872A1 (en) 2022-11-10
TW202309051A (zh) 2023-03-01
IL308099A (en) 2023-12-01
CA3217403A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
AU2022269811A1 (en) Orexin receptor agonists and uses thereof
JP7264810B2 (ja) アルファｖインテグリン阻害剤としてのシクロブタン－およびアゼチジン－含有の単環およびスピロ環式化合物
WO2023275301A1 (en) Imidazotriazine derivatives as il-17 modulators
EP4284365A1 (en) Cdk2 inhibitors and methods of using the same
AU2016311376A1 (en) Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators
WO2021170631A1 (en) Difluorocyclohexyl derivatives as il-17 modulators
JP2024541758A (ja) Ｅｇｆｒキナーゼの分解のための化合物
EP4132650A1 (en) Difluorocyclohexyl derivatives as il-17 modulators
AU2024206808A1 (en) Organic compounds as nlrp3 inhibitors
US20260042755A1 (en) Gpr6 inverse agonists
JP2025538190A (ja) Ｅｇｆｒキナーゼの分解のための化合物
WO2024026479A2 (en) Cdk2 inhibitors and methods of using the same
TW202412784A (zh) 氮-喹唑啉化合物及使用方法
RS66095B1 (sr) N-(imidazo[1,2 b] piridazin 3 1 cikloheksil 2h indazol 5 karboksamid i n-(pirazolo[1,5 a] pirimidin 3 1 cikloheksil 2h indazol 5 karboksamid derivati kao irak4 inhibitori za lečenje astme
JP2023520006A (ja) Ｓｓｔｒ４アゴニストとしてのｎ－（ヘテロシクリル及びヘテロシクリルアルキル）－３－ベンジルピリジン－２－アミン誘導体
US20240425523A1 (en) Compounds for the Degradation of EGFR Kinase
AU2023281216A1 (en) Macrocyclic orexin receptor agonists and uses thereof
CA3222054A1 (en) 2, 8-diazaspiro[4.5]decane compounds
EP4558481A1 (en) Emopamil-binding protein inhibitors and uses thereof
WO2025245351A1 (en) Substituted aryl sulfonamides and compositions and uses thereof
TW202444724A (zh) 大環食慾激素受體促效劑及其用途
HK40029777A (en) Receptor inhibitor, pharmaceutical composition comprising same, and use thereof